FDMT Stock — 4D Molecular Therapeutics, Inc.

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 7, 2026

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Neutral Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 20.7 · elevated Equity put/call 0.61

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −2%

below

Price vs 50-day avg −8%

below

RSI (14) 37

neutral

MACD trend Negative

52-week position 55%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Neutral

1-month return −28%

trailing

6-month return +3%

trailing

YTD return +28%

this year

Relative strength −3%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $10 › 200d $10 — 50d above 200d

Institutional flow Distributing

27 of 152 funds reported for Jun 30 · net -260.3K sh shares · +4 new

Insider flow Distributing

Net -$19.3K over 90 days · 100% sells

Short interest Falling

16.42% of float · ▼ -14.6% MoM · 15.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

152 holders — near 3-yr high, broad support

Squeeze score 70

elevated · 0–100

Fundamentals

Strong

Revenue growth +230195%

Y/Y

EPS growth +19%

Y/Y

Free cash flow $-109.6M

Balance sheet $60.2M

net cash

Quant / Vol

risk profile

Very High

Volatility 93%

annualized · 1-yr

Max drawdown −41%

past year

ATR 8.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

2 · 5 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−2% Neutral

Price vs 50-day avg

−8% Bearish

RSI (14)

37 Neutral

MACD trend

Negative Bearish

52-week position

55% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $10 › 200d $10 — 50d above 200d

Institutional flow Distributing

27 of 152 funds reported for Jun 30 · net -260.3K sh shares · +4 new

Insider flow Distributing

Net -$19.3K over 90 days · 100% sells

Short interest Falling

16.42% of float · ▼ -14.6% MoM · 15.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

152 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $4 Now $10 · 55% 52-wk high $14

vs 200-day avg -2% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Cash, cash equivalents and marketable securities	$458M	Q1 2026	—
Upfront cash payment received from Otsuka	$3.05M	FY2026 Q1	+21664.3%

First tranche of CF Foundation equity investment received	$7.5M	full year 2025	—
Gross proceeds from at-the-market offering	$10M	full year 2025	—
Gross proceeds from November 2025 equity offering	$100M	full year 2025	—
Net proceeds from November 2025 equity offering	$93M	full year 2025	—
Target enrollment for 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials	480	full year 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
FDMT 4D Molecular Therapeutics, Inc. this stock	$681.74M	+28.1%	+230194.6%	—	16.4%
ONC BeOne Medicines Ltd.	$472.90B	+7.7%	+22179.2%	962.4	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$122.67B	+6.6%	+46.2%	28.7	2.0%
REGN Regeneron Pharmaceuticals, Inc.	$72.91B	-9.8%	+20.8%	17.0	3.3%
ARGX Argenx SE	$54.57B	+4.9%	—	—	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

151

% held: 73.1%
Reported: 27 of 152
Top holder: JANUS HENDERSON GROUP PLC

Held Float

View

Held by Funds

Fund positions

162

View

Short & Settlement

Short Interest Falling

Shares short

11.4M

Days to cover: 15.5d
Change: -1.9M sh

View

Short Volume

Short vol %

72%

As of: Jul 29, 2026

Short Total

View

Fails to Deliver

FTD shares

963

Value: $12.4K
As of: Jun 30, 2026

View

Off-Exchange

Off-exchange %

48.6%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$19.3K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Revenue (FY)

$85.2M

Net income (FY): $-140.1M
EPS diluted: $-2.42

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 20, 2026
This year: 15

View

Proposed Sales

Value

$84.6K

Shares: 6.6K
Filed: Jun 30, 2026

View

Earnings & Events

Earnings Calls

Last call

Jun 9, 2026

View

	5D	20D	120D	MTD	YTD
FDMT	-12.3%	-27.7%	+3.4%	-27.7%	+28.1%
SPY	-2.4%	-2.3%	+6.3%	-2.3%	+7.0%
vs SPY	-9.9%	-25.4%	-2.9%	-25.4%	+21.2%

FDMT · 4D Molecular Therapeutics, Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance